Presentation Stock market days at Aktiespararna
June, 2025
Presenter:
Martin Åmark, CEO
Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.
We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.
We develop biosimilars in treatment of macular degeneration (Xlucane™) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion
June, 2025
Presenter:
Martin Åmark, CEO
05 May 2026
Xbrane Biopharma AB’s (publ.) (”Xbrane”) Interim Report January-March 2026, is as of today, available on the Company’s website, www.xbrane.com.
05 May 2026
Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities
31 Mar 2026
Xbrane provides an update on the timeline for resubmission of the market authorization application in the United States